Before revision:   These results highlight the urgent need for prospective trials testing whether prophylactic \alpha-blockers improve outcomes in diseases with a prominent hyperinflammatory component such as COVID-19.
After revision:  These results highlight the urgent need for prospective trials testing whether prophylactic use of \alpha_1-AR antagonists ameliorates diseases associated with cytokine storm syndrome, such as COVID-19.